Array Biopharma (ARRY) Tops Q2 EPS by 4c

Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.

COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July

NEMO / NRAS-mutant melanoma target action date under the Prescription Drug User Fee Act (PDUFA) on June 30, 2017

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• AbbVie updates 2026 EPS guidance after $291M IPR&D charge